Staging for vulvar cancer

Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):802-11. doi: 10.1016/j.bpobgyn.2015.01.004. Epub 2015 Mar 4.

Abstract

Vulvar cancer has been staged by the International Federation of Gynaecology and Obstetrics (FIGO) since 1969, and the original staging system was based on clinical findings only. This system provided a very good spread of prognostic groupings. Because vulvar cancer is virtually always treated surgically, the status of the lymph nodes is the most important prognostic factor and this can only be determined with certainty by histological examination of resected lymph nodes, FIGO introduced a surgical staging system in 1988. This was modified in 1994 to include a category of microinvasive vulvar cancer (stage IA), because such patients have virtually no risk of lymph node metastases. This system did not give a reasonably even spread of prognostic groupings. In addition, patients with stage III disease were shown to be a heterogeneous group prognostically, and the number of positive nodes and the morphology of those nodes were not taken into account. A new surgical staging system for vulvar cancer was introduced by FIGO in 2009. Initial retrospective analyses have suggested that this new staging system has overcome the major deficiencies in the 1994 system.

Keywords: FIGO; staging; vulvar cancer.

Publication types

  • Review

MeSH terms

  • Carcinoma, Squamous Cell / pathology*
  • Carcinoma, Squamous Cell / surgery
  • Female
  • Groin
  • Humans
  • Lymph Node Excision
  • Lymph Nodes / pathology*
  • Neoplasm Staging
  • Prognosis
  • Tumor Burden
  • Vulvar Neoplasms / pathology*
  • Vulvar Neoplasms / surgery